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Gabapentin and pregabalin in the 
pain setting: All you need to know
Abstract
The last decade has seen a marked increase in the use of 
gabapentinoid drugs for pain management. This, in part, reflects the 
shift from some non-steroidal anti-inflammatory drugs (NSAIDs), 
as well as issues arising from the protracted use of opioids. More 
extensive use of gabapentin and pregabalin, has seen the clinical 
role widen to incorporate a range of unlicensed pain scenarios, as 
well as increased medicines’ costs. 
   The evidence for efficacy in some pain conditions, namely post-
herpetic neuralgia and diabetic neuropathic pain, is stronger than 
for non-neuropathic pain conditions, such as fibromyalgia. Anxiolytic 
properties, as well as widespread availability, have encouraged 
recreational misuse, which is associated with doses outside the 
therapeutic range. 
   Safe use for neuropathic pain (central and peripheral), complex 
pain, migraine, and the evidence for some non-neuropathic pain 
conditions will be discussed, as well as the emerging abuse issues. 
Anti-convulsant interventions will not be covered in this article, nor 
will use in children.
Key words: Gabapentin; pregabalin; neuropathic pain; adjuvant pain 
drugs; misuse
Sharon Rees 
Associate Professor Therapeutics and Prescribing, 
London South Bank University
sharon.rees@lsbu.ac.uk 
Sharon Rees
Originally licensed as anticonvulsants, the gabapentinoid drugs, namely gabapentin and 
pregabalin, have become popular agents in the pain 
setting. Known as adjuvant pain medications, because 
their primary class of action is not as analgesics, 
prescriptions for these drugs have increased 
exponentially in the UK, by 150% (gabapentin) and 
350% (pregabalin) between 2011 and 2016 (Spence, 
2013; Iverson, 2016). 
Traditionally, the main use of gabapentinoids 
has been for the relief of neuropathic pain, and, in 
the context of licensed use, specifically peripheral 
neuropathic pain (gabapentin) and peripheral and 
central neuropathic pain (pregabalin) (Joint Formulary 
Committee, 2018). Gabapentin was licensed as an 
anti-epileptic in the UK in 1993, and pregabalin in 2004 
(Morrison et al, 2017).
The gabapentinoids act by inhibiting calcium 
currents on central nervous system (CNS) pre-
synaptic neurons, suppressing nerve signalling. While 
there is no proven direct effect on the inhibitory 
neurotransmitter GABA, there are putative effects on 
many neurotransmitter systems, including GABA and 
the monoamines (Eroglu et al, 2009) (Table 1). The 
ability to modulate pain pathways may be the reason 
why neuropathic pain responds to these drugs, while 
treatment with traditional analgesics has been less 
successful (Chen et al, 2004).
The explanation for the significant increase in 
prescribing for chronic pain conditions, and, in 
particular, the use of gabapentinoids, over the last 
decade, is unclear. Some increase is likely to be related 
to the search for alternatives to traditional pain relief 
options, given the safety issues associated with using 
many of the most common and popular analgesics, 
namely opioids, co-proxamol (now excluded) and drugs 
with analgesic activity, such as non-steroidal anti-
inflammatory drugs (NSAIDs). Furthermore, marketing 
claims in the 1990s, promoting gabapentinoid use 
for unapproved conditions, such as non-neuropathic 
pain, may well have perpetuated the expansion of 
prescription use (Steinman et al, 2006). The practice 
of off-label prescribing appears to have taken hold, 
despite acknowledged violations of legal marketing 
boundaries (Newman, 2010; Ghinea et al, 2015) and 
subsequent clarification of approved indications for use. 
All prescribers are able to prescribe outside the licensed 
indications for a given drug, but it is incumbent on 
the clinician to have first ensured that this decision 
meets certain criteria. These include acceptable efficacy, 
no licensed alternative that is suitable, and that the 
decision is in the patient’s best interests (Medicines 
and Healthcare products Regulatory Agency (MHRA), 
2009). The responsibility for any greater risks to 
the patient lies with the prescribing clinician and 
appropriate counselling relating to safe use must be in 
place (MHRA, 2009).
Cochrane reports by Wiffen et al (2017) and Moore 
et al (2009) supported benefits for gabapentin and 
pregabalin, respectively, for post-herpetic neuralgia and 
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painful diabetic neuropathy. However, weaker evidence 
for other types of neuropathic pain, such as cancer 
nerve pain and complex regional pain syndrome was 
found (Wiffen et al, 2017). The mean number needed  
to harm (NNH) for all cause neuropathic pain, based 
on at least one adverse event was 7.5 for gabapentin, 
at a daily dose of >1200mg, although the NNH for 
serious events was not calculated (Wiffen et al, 2017). 
Pregabalin data showed a NNH for 300 mg at 6.6, 
representing at least one adverse event or serious 
adverse event (Moore et al, 2009).
Mechanism of action
Gabapentin and pregabalin are structurally related and 
appear to share the same mechanism(s) of action, but 
the full mechanism of action remains unclear. As the 
names suggest, these are analogues of the inhibitory 
neurotransmitter GABA, and although this was the 
rationale behind their development, they do not act on 
GABAA or GABAB receptors directly (Taylor et al, 1998). 
Central nervous system neurons transmit signals based 
on neurotransmitter types and levels at the synapse, 
and the degree of excitability of the nerve (propensity 
to propagate the signal). The extent of neurotransmitter 
availability relies on the influx of calcium ions, as this 
triggers neurotransmitter release. The calcium channel 
can be used as a switch. By modifying calcium flow, 
neurotransmitter disposal and the signal strength will 
increase or decrease. 
Gabapentin and pregabalin both act to bind to a 
sub-unit on the voltage-gated calcium channels (α2δ). 
This causes a narrowing of the channel, and ultimately 
decreases the amplitude of pain signals; therefore, less 
pain is perceived. Pregabalin binding has a stronger 
affinity for the channel, hence the higher potency 
(Jones and Sorkin, 1998) (Table 2). This suppression 
of neuron signalling is non-specific, exerting general 
effects on nociceptive pathways. It is thought that 
there are differences in the pain signals arising from 
damaged nerves, for example an up-regulation of the 
α2δ calcium channel subunit in damaged nerves (Alles 
and Smith, 2016), compared to the signals emitted 
from damaged tissues. Efficacy in neuropathic pain 
could relate to this mechanism of action (Chen et 
al, 2018). It is relevant that the non-specific effects 
may also manifest as neurotoxic events, such as 
sedation, cognitive dysfunction, respiratory depression 
and visual disturbances (electronic Medicines 
Compendium, 2017; 2018). 
A further consequence of gabapentinoid 
administration is elevated central GABA levels, 
which is why these drugs are useful in seizure control 
(Treimann, 2001). A variety of interactions with GABA 
systems, and modulation of other pain targets are noted, 
although some are based on animal models and the full 
picture remains speculative. Therefore, by enhancing 
the inhibitory effects of GABA, less excitatory 
glutamate is functional and lower levels of monoamine 
neurotransmitters are released, all of which suppress 
pain signalling (Cunningham et al, 2004; Bauer et al, 
2010; Cai et al, 2012).
Pharmacokinetics 
and clinical profile
The faster absorption of pregabalin allows a rapid onset 
of action (Guay, 2005). Gabapentin does not follow 
first order kinetics because its absorption systems 
are saturable. In practical terms, this means that a 
higher dose is linked to lower bioavailability. There is 
no relevant plasma protein binding for either drug, a 
feature helpful for minimising drug–drug interactions 
Table 1. Potential effects of gabapentinoid drugs on neural pathways 
Receptor/ Target Effect on pain Reference 
α2δ1 subunit on high voltage activated 
calcium channel
Reduces pain signal transmission Gee et al (1996)
Eroglu et al (2009)
Vallinoid receptor 1 (TrpV1) Blocks sensory nerve pain transmission Kim et al (2014)
NMDA receptor Inhibition of the NMDA receptor blocks glutamate function Hara and Sata 
(2007)
Yang et al (2009)
α2 adrenergic receptors Enhance descending pain inhibition
Anti-allodynic effects attributed to this
Tanabe et al 
(2005)
Decreased release norepinephrine, 
glutamate, substance P
Lower levels excitatory neurotransmitters means less pain 
perception
Stahl (2004)
Martinotti et al 
(2013)
Glutamic acid decarboxylase (GAD) 
(stimulates GABA)
By increasing levels, more GABA produced Taylor (1997)
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Table 2. Gabapentin and pregabalin: key characteristics 
for pain uses
Parameter Gabapentin Pregabalin
Indication for use 
(pain related only)
Peripheral neuropathic pain
Migraine prophylaxis
Peripheral and central 
neuropathic pain
Dose range (minimum level 
efficacious for neuropathic pain)
1200-3600 mg/day
(Wiffen et al, 2017)
300–600 mg/day
(Moore et al, 2009)
Time to Cmax /bioavailability 2–3 hours/60% 1 hour/>90%
Potency Less potent 2.8–6 times more potent 
Half life 5–7 hours 6.3 hours
Metabolism none none
Excretion Renal (unchanged drug) Renal (unchanged drug)
Very common (≥ 1/10), 
or common adverse drug 
reaction 
(≥1/100 to <1/10) 
Dizziness, somnolence  
and fatigue
Increased appetite
Peripheral oedema 
Dizziness and somnolence
Increased appetite
Peripheral oedema
Serious adverse drug reaction 
(NOT exhaustive list)
Pneumonia
Leucopenia
Psychiatric reactions 
Pancreatitis 
Rhabdomyolysis 
Psychiatric reactions 
Convulsions
Congestive cardiac failure
Drug–drug interactions CNS depressants, e.g. opiates 
and benzodiazepines
(potentiation of effects)
CNS depressants e.g. 
opiates and benzodiazepines
(potentiation of effects)
Drug–disease interactions Diabetes mellitus
Elderly
History psychotic illness
Mixed seizures
Conditions that may precipitate 
encephalopathy
Severe congestive cardiac failure 
Additional cautions High risk of respiratory depression 
e.g. in elderly and those on CNS 
depressants (see MHRA warning)
Withdrawal timeline Over minimum one week over minimum one week
Cost (drug tariff price) * £3.24 £64.40
CNS—central nervous system
*Based on highest dose for neuropathic pain for one month using the cheapest option
From:  electronic Medicines Compendium (2017);  Medicines and Healthcare products Regulatory Agency (2017); electronic Medicines 
Compendium (2018); Joint Formulary Committee (2018);
and adverse drug reactions (Johannessen Landmark 
and Patsalos, 2010).
One of the major advantages of this drug class is 
that they are not metabolised in the liver (Patsalos, 
2013). This removes one of the most frequent causes 
of drug–drug interactions, that of phase 1 metabolism 
changes effected by other drugs. However, the lack 
of biotransformation does mean that the majority 
of these drugs are excreted whole by the kidneys 
(>98%) (Bockbrader et al, 2010). In situations where 
renal function is sufficiently compromised, the 
reduced clearance will mean less drug is eliminated 
and more whole drug will circulate for longer. This 
has implications for toxicity and the dose should be 
adjusted accordingly.
Central neuropathic pain
Central neuropathic pain can occur following CNS 
injury, with stroke being a common cause (Bowsher, 
1996). It can be difficult to distinguish from peripheral 
pain, since the impact on peripheral structures, such 
as muscle denervation, spasticity and overuse of 
unaffected sites, can produce pain. Clearly, these can 
coexist, complicating the pain-generating diagnosis 
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and management. Pregabalin is licensed for central 
neuropathic pain management and is used post-stroke, 
for multiple sclerosis and for pain associated with spinal 
cord injury (Watson and Sandroni, 2016). 
Although unlicensed for central neuropathic 
pain, gabapentin is included in the National Institute 
for Health and Care Excellence (NICE) guidance, 
European Federation of Neurological Societies (EFNS) 
and the Canadian Pain Society recommendations 
for post-stroke central neuropathic pain (Attal et al, 
2010; Moulin et al, 2014). The EFNS and the NICE 
guidelines for neuropathic pain do not distinguish 
between central and peripheral neuropathic 
pain (NICE, 2018a; Attal et al, 2010), hence both 
anticonvulsants appear in the guidelines.
A large systematic review conducted by Mulla et 
al (2015) suggested over-statement of many studies 
regarding the effect(s) of all interventions for central 
neuropathic pain, including for the anti-convulsants. 
Publication bias is also acknowledged by Finnerup et 
al (2015) regarding drugs used in neuropathic pain by 
up to 10%. They report ‘modest’ efficacy for gabapentin 
and pregabalin, at a number needed to treat (NNT) of 
7.2 (5.9-9.21) and 7.7 (6.5-9.4), respectively. In clinical 
terms, this means that for every 7-8 patients, one will 
experience 50% or more reduction in neuropathic pain, 
when compared to placebo. 
Complex pain
In common with other chronic pain syndromes, 
neuropathic pain can involve central sensitisation 
(Woolf, 2011). This can lock someone into a ‘pain loop’ 
from which it can be hard to escape, making effective 
treatment problematic. For example, following some 
cases of nerve injury, complex regional pain syndrome 
(CRPS) can occur, although nerve damage is not always 
the cause (Rockett, 2014). This atypical and chronic 
reaction to injury is often disproportionate to the 
injury level and can be severe and intractable (Rockett, 
2014). O’Connell et al’s (2013) Cochrane review does 
not recommend a drug for neuropathic pain is used 
in CRPS, stating the current evidence for any effective 
intervention is of poor quality. 
A common form of nerve injury is radiculopathy, a 
compression syndrome originating at the ‘root’ of the 
nerve, e.g sciatic nerve, producing radiating pain. The 
approach is for first line drug intervention with NSAIDs 
and/or opioids, but if pain remains uncontrolled, an 
agent for neuropathic pain can be considered (NICE, 
2017a). The choice includes the gabapentinoids, but no 
one agent is recommended as superior, selection being 
made on the optimal agent for the individual.
Phantom limb pain is another example of 
complex and severe pain, which is suggested to 
have a neuropathic element (Wiffen et al, 2017). For 
such conditions, only some people respond to the 
gabapentinoid drugs, which is unsurprising due to the 
complexity of the pain pathways and the individual 
responses to chronic pain. The evidence remains 
conflicted (Alviar et al, 2011; O’Connell et al, 2013) 
and a personalised approach to complex pain may  
be necessary.
Painful diabetic neuropathy
The strongest evidence for use is for neuropathic pain, 
of which painful diabetic neuropathy is a common 
cause (Dieleman et al, 2008). The NICE Clinical 
Knowledge Summaries (CKS) do not differentiate 
between a number of different drug classes as first-
line interventions, allowing the clinician to select the 
most appropriate for the individual (NICE, 2015). 
However, the gabapentinoids are popular options 
(Rajan et al, 2014). The mean NNTis reported as 5.9 for 
gabapentin (Wiffen et al, 2017), and 5 for pregabalin 
(Moore et al, 2009), compared to placebo. Advantages 
include safe use with other medications, a particular 
benefit for the diabetic population given the frequency 
of polypharmacy. They are generally well-tolerated, 
although weight gain is a common side effect and can 
be an issue, with particular health implications in the 
diabetic population (Box 1).
Post-herpetic neuralgia
Damage from the varicella zoster virus represents 
one of the most painful nerve syndromes (Johnson, 
2007), and is associated with burning, stabbing pain, 
sensory deficits, sleep disturbance and depression 
(Beal et al, 2012). There is a well-defined role for 
using the gabapentinoids for pain relief, with a mean 
NNT of 6.7 for gabapentin (Wiffen et al, 2017) and 
3.9 for pregabalin (Moore et al, 2009). If the pain is 
uncontrolled with simple analgesics and practical 
steps such as loose clothing, NICE recommend 
pharmacological intervention as per neuropathic pain. 
No single drug on the neuropathic pain pathway is 
recommended over another (NICE, 2017b).
Migraine
Despite ‘migraine prophylaxis’ being an indication 
for gabapentin, this is an unlicensed use for the drug. 
Box 1. Putative mechanisms for
weight gain (mainly from 
anticonvulsant usage) 
■ Increased appetite
■ 
Food cravings
 Slowed metabolism
■ Fatigue
■ Water retention
■ Less pain, enabling more socialising
(Jallon and Picard 2001, Domecq et al 2015)
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Pregabalin is neither indicated, nor licensed, for use 
in this setting. As a cause of complex and sometimes 
intractable pain, migraine was one of the conditions for 
which gabapentin ‘expanded’ into trials and off-label 
use (Di-Trapani et al, 2000; Spira et al, 2003). However, 
a Cochrane review by Linde et al (2013) found that it 
was not an effective intervention to prevent migraine 
and recommended that it should not be routinely 
prescribed. Accordingly, the CKS pathway does not 
include gabapentin as a drug option (NICE, 2018b).
Fibromyalgia
The chronic pain associated with fibromyalgia is 
notoriously complex and multi-dimensional, but it is 
not classified as a neuropathic condition. In Canada 
and the US, pregabalin is licensed for fibromyalgia, 
but this is not the case for Europe. Derry et al (2016) 
reported that pregabalin can work for a sub-set (10%) 
of fibromyalgia patients to improve pain. In those who 
do not respond with pain relief, there may be other 
benefits, such as improved quality of life and function 
(Derry et al, 2016). The evidence for gabapentin was 
weaker, and Cooper et al’s (2017) Cochrane review was 
inconclusive regarding a beneficial effect. More recent 
approaches to fibromyalgia include pain management 
programmes, which aim to place the patient at the 
centre in controlling their own pain (Wilkinson and 
Whiteman, 2017).
Acute and post-operative pain
Uses for the gabapentinoids in acute pain have emerged. 
There is most evidence for its use in post-operative 
pain. One of the areas in which prescribing has 
increased is following spinal surgery. Other uses have 
been primarily where acute pain may have an atypical 
or possibly neuropathic dimension, such as with burn 
injury. While the current literature supporting this is 
mostly case studies, future research may better inform 
clinical practice. 
After surgery there is an up-regulation of calcium 
channels on neurons, because of the increase in cell 
signal traffic (Bauer et al, 2010). This positions the 
gabapentinoids as a theoretically useful approach in 
post-surgical pain, with particular advantages for 
neurosurgeries, as the α2δ1 calcium channel subunit 
is predominantly expressed in the dorsal horn (Bauer 
et al, 2010). However, the effects on acute pain are 
controversial, as the majority of evidence is for chronic 
and neuropathic pain. A Cochrane review found a 
positive effect of gabapentin on acute pain, but an 
NNT of 11. While this showed that a single dose of 
250 mg could reduce acute pain, it was inferior to 
standard NSAIDs and paracetamol interventions 
(Straube et al, 2010). 
Other studies have shown that there is an opioid-
sparing effect when using the gabapentinoids in the 
post-operative situation, with related advantages in 
reducing opioid adverse reactions, such as nausea 
and vomiting. This comes at the expense of the 
gabapentinoid adverse drug reaction profile that 
includes sedation and visual disturbances (Tiippana et 
al, 2007). It is noteworthy that no evidence supports 
use after surgery, to achieve prevention of chronic 
post-operative pain (Martinez et al, 2017). Public 
Health England (PHE) state that prescribing for 
non-neuropathic pain is not evidence-based (PHE, 
2014). While acute pain represents an interesting 
application for these drugs, the evidence-base is mainly 
experimental and such prescribing is likely to be by 
specialist teams only.
Discontinuation 
Drugs acting on CNS signalling systems exert complex 
effects, which are not fully understood, but it is known 
that certain drugs acting on these systems must be 
initiated and withdrawn with care (Parsons, 2018). 
GABA is the main fast inhibitory neurotransmitter in 
the CNS and is formed from glutamate, which is the 
main fast excitatory neurotransmitter (Huang  and  
Thathiah, 2015). This relationship allows tightly coupled 
control of neural signalling, which also involves a 
multitude of other neurotransmitters and receptors. 
As with all psychotropic drugs, neurotransmitter 
function(s) and signalling systems in central nervous 
system neuronal pathways become altered possibly 
because of changes to receptor expression (Cai et 
al, 2012). Accordingly, the regimen for use typically 
involves gradual adjustment to the dose, and careful 
titration to effective levels. If stopped abruptly, the CNS 
does not have the chance to re-adjust and this can lead 
to disruption of function around the new ‘set points’. 
The scenarios studied for withdrawal relate to seizure 
control, as opposed to neuropathic pain (UK Medicines 
Information, 2015), making the effects of adjustment 
within the pain dose ranges theoretical.
Regarding GABA concentration changes, cessation 
can have features similar to withdrawal from 
benzodiazepines and alcohol, as both of these also alter 
Box 2. Safe use of gabapentinoids
■ Careful titration: start low and go slow
■ Discount if not effective (usually allow at least 8 weeks  
for effect)
■ If effective, titrate down to minimal effective level
■ Counselling for benefits versus side effects and drug driving
■ Warn about dependence and clarify distinction with addiction
■ Check history of substance abuse
■ Care if being co-prescribed with opiates
■ Do not stop suddenly
■ If unlicensed use, ensure patient gives informed consent.
From: National Institute for Health and Care Excellence (NICE) (2015); NICE (2018a); 
PrescQuipp (2016); Public Health England (2014) 
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GABA function (Lobo and Harris, 2008). Withdrawal 
symptoms can be unpleasant, namely insomnia, 
irritability, headaches, gastrointestinal upset and can 
result in tachycardia, seizures and psychiatric reactions, 
such as suicidal ideation (Mersfelder and Nichols, 
2016; Parsons, 2018). Occurrence of these symptoms 
does not represent ‘addiction’ to the drug, although 
this is a common misconception. Addiction is defined 
by compulsive drug-seeking behaviour and continued 
use, despite recognition of harm (American Society of 
Addiction Medicine (ASAM), 2011). It is important 
that this distinction is made clear to patients, in order to 
support safe use and concordance (Box 2).
The recommended tapering procedure is to reduce 
the dose over a minimum of 1 week (eMC, 2017; 2018), 
although the British National Formulary (BNF) only 
states this for pregabalin (Joint Formulary Committee, 
2018). However, when used in the pain setting, more 
gradual discontinuation is helpful to monitor the 
effect(s) of stoppage on the background condition 
(PHE, 2014). PHE recommend: 
 ■ Pregabalin: reduce the daily dose at a maximum of 
50–100 mg/week 
 ■ Gabapentin: reduce the daily dose at a maximum 
rate of 300 mg every 4 days. 
If one or the other drug does not work, only partially 
work, or is not tolerated, it is possible to switch 
from one to the other. The cross-tapering protocol is 
approached in one of two ways. The first is to stop, 
using the formal discontinuation stages over at least 
1 week (or longer, see above) and then to start to titrate 
up the alternative drug. This may allow breakthrough 
pain. The second is to start titrating in the other 
drug before full discontinuation until pain relief is 
established (PrescQipp, 2016).
Misuse
Greater prescription use and wider acknowledgement  
of gabapentinoid properties have fuelled a significant 
black market, abetted by online purchasing, e.g. 
using online pharmacies (Schifano et al, 2011). 
The current status as a ‘prescription only medicine’ 
and ‘uncontrolled’ drug group, which has not 
traditionally had an ‘abuse’ reputation, means that 
the gabapentinoids are excluded from the standard 
drug monitoring procedures. This has enabled 
illicit purchasing and abuse, under the radar of the 
authorities, both of which are particularly prevalent in 
the prison population and in addiction clinics (Recoppa 
et al, 2004; Smith et al, 2012; Baird et al 2014).
In the UK, this misuse has led to the Advisory 
Council for the Misuse of Drugs (ACMD) 
investigating the clinical and abuse roles of gabapentin 
and pregabalin, with a view to re-classification as 
controlled drugs. Growing evidence of harm has been 
reported from the increased number of deaths citing 
these drugs (1 and 4 in 2009 to 26 and 38 in 2014, 
respectively (Office for National Statistics, 2016), 
as well as rising emergency department admissions 
(Millar et al, 2013).  The latest information in Spring 
2018 is agreement from the Government to accept the 
ACMD advice to re-classify pregabalin as a class C 
drug, after analysis from the public consultation has 
been completed (Iacobucci, 2017).
The characteristics of the gabapentinoids that 
encourage misuse include the ability to mix with 
many other medical and recreational drugs, such as 
alcohol, opioids, cannabis, selective serotonin reuptake 
inhibitors and amphetamines (Smith et al, 2012; Smith 
et al, 2016). When mixed, the potential for harm is 
significantly increased, causing sedation, respiratory 
failure and death (Lyndon et al, 2017). Both gabapentin 
and pregabalin can produce relaxation and elevated 
mood and, if crushed and inhaled nasally, can produce 
a ‘high’ similar to cocaine (Schifano et al, 2011). 
Furthermore, both may be used to potentiate the effects 
of methadone (Baird et al, 2014) and are used as cutting 
agents for heroin (Smith et al 2012). 
Pregabalin was made a scheduled drug in the US in 
2005 (schedule V), reflecting its higher abuse potential. 
This is probably related to its greater potency and there 
being a faster onset of action (Häkkinen et al 2014).  
There are calls for gabapentin to be ‘scheduled’ in the 
US too, particularly following a systematic review 
by Smith et al (2016) looking into gabapentin abuse 
in the US and Europe. Findings included a general 
population misuse rate of 1%, but this increased up to 
65% for people with other prescriptions. The review 
found a strong relationship between opioid use (Wilens 
et al, 2015) and alcohol use (Häkkinen et al, 2014; 
Schifano et al, 2011) and gabapentin. Certainly, in the 
UK, it is already recommended that these drugs are 
only prescribed to people with a history of substance 
abuse, after the benefits and risks have been carefully 
considered (PHE, 2014). For this group, the preferred 
first line agent for neuropathic pain is amitriptyline 
(PrescQipp, 2016).
Perhaps ironically, pregabalin is also used to 
help manage alcohol, benzodiazepine and narcotic 
withdrawal (Oulis et al, 2012; Freynhagen et al, 2016), 
because a number of its effects relate to suppression of 
neuronal excitability. The very properties that make 
it suitable for a range of psychiatric and neurological 
conditions, also make it subject to abuse. It should 
be noted that the doses applied for medical use are 
effective within the therapeutic range, permitting 
intervention with a low risk of harm or abuse. Indeed, 
within dose range, and as monotherapy, these drugs are 
considered safe.
Conclusion
There is strong evidence to support the use of the 
gabapentinoids for two common neuropathic pain 
conditions: painful diabetic neuropathy and post-
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herpetic neuralgia. Clinical efficacy is less certain for 
other types of neuropathic pain and caution should be 
exercised, even for other causes of pain either known, 
or perceived to be, neuropathic. There is a lack of 
compelling evidence for all other uses and the local pain 
pathway and up-to-date guidelines should be consulted, 
to ensure prescribing conforms to current best practice.
In view of the unlicensed status for other pain uses, 
and the potential for harm, clinicians should be fully 
aware of the relevant accountabilities in such scenarios. 
Exemplary counselling and support during use should 
help minimise safety issues. The growing misuse of 
this drug class is likely to focus clinical usage in the 
near future and it is clear that those with a history of 
recreational misuse (of any drug class) should avoid 
these drugs. Approaches to chronic pain management 
are slowly changing and the trend towards viewing 
complex pain though a non-pharmacological lens is 
growing, particularly as the harmful aspects of drug 
interventions are exposed.
Alles SR, Smith PA. The anti-allodynic gabapentinoids: myths, 
paradoxes, and acute effects. Neuroscientist. 2016. https://doi.
org/10.1177/1073858416628793.
Alviar MJ, Hale T, Dungca M. Pharmacologic interventions for 
treating phantom limb pain. Cochrane Database Syst Rev. 
2011;(12):CD006380. https://doi.org/10.1002/14651858.
CD006380.pub2 
American Society of Addiction Medicine. Public Policy Statement: 
Short Definition of Addiction. 2011. www.asam.org/docs/
default-source/public-policy-statements/1definition_of_
addiction_short_4-11.pdf?sfvrsn=6e36cc2_0. (accessed 11 
April 2018)
Attal N, Cruccu G, Baron R et al. EFNS guidelines on the 
pharmacological treatment of neuropathic pain: 2010 revision. 
Eur J Neurol. 2010;17(9):1113-e88. https://doi.org/10.1111/
j.1468-1331.2010.02999.x 
Baird CRW, Fox P, Colvin LA. Gabapentinoid abuse in order to 
potentiate the effect of methadone: a survey among substance 
misusers. Eur Addict Res. 2014;20(3):115–118. https://doi.
org/10.1159/000355268
Bauer CS, Tran-Van-Minh A, Kadurin I, Dolphin AC. A new 
look at calcium channel α2δ subunits. Curr Opin Neurobiol. 
2010;20(5):563–571.https://doi.org/10.1016/j.conb.2010.05.007
Beal B, Moeller-Bertram T, Schilling JM, Wallace MS. Gabapentin 
for once-daily treatment of post-herpetic neuralgia: a review. 
Clin Interv Aging. 2012;7:249–255.
Joint Formulary Committee. British National Formulary. London: 
BMJ Group and Pharmaceutical Press: 2018
Bockbrader HN, Wesche D, Miller R, Chapel S, Janiczek 
N, Burger P. A comparison of the pharmacokinetics 
and pharmacodynamics of pregabalin and gabapentin. 
Clin Pharmacokinet. 2010;49(10):661–669. https://doi.
org/10.2165/11536200-000000000-00000
Bowsher D. Central pain: clinical and physiological characteristics. 
J Neurol Neurosurg Psychiatry. 1996;61(1):62–69. https://doi.
org/10.1136/jnnp.61.1.62 Medline
Cai K, Nanga RPR, Lamprou L et al. The impact of gabapentin 
administration on brain GABA and glutamate concentrations: 
a 7T ¹H-MRS study. Neuropsychopharmacology. 
2012;37(13):2764–2771. https://doi.org/10.1038/npp.2012.142
Chen J, Li L, Chen SR et al. The α2δ-1-NMDA receptor complex 
is critically involved in neuropathic pain development and 
gabapentin therapeutic actions. Cell Rep 27;22(9):2307-2321. 
https://doi.org/10.1016/j.celrep.2018.02.021 
Chen H, Lamer TJ, Rho RH, Marshall KA, Sitzman BT, Ghazi SM, 
Brewer RP. Contemporary management of neuropathic pain for 
the primary care physician. Mayo Clin Proc. 2004;79(12):1533–
1545. https://doi.org/10.4065/79.12.1533
Cooper TE, Derry S, Wiffen PJ, Moore RA. Gabapentin for 
fibromyalgia pain in adults. Cochrane Database Syst Rev. 2017 
;1(1):CD012188. https://doi.org/10.1002/14651858.CD012188.
pub2
Cunningham MO, Woodhall GL, Thompson SE, Dooley DJ, Jones 
RSG. Dual effects of gabapentin and pregabalin on glutamate 
release at rat entorhinal synapses in vitro. Eur J Neurosci. 
2004;20(6):1566–1576. https://doi.org/10.1111/j.1460-
9568.2004.03625.x
Derry S, Cording M, Wiffen PJ, Law S, Phillips T, Moore RA. 
Pregabalin for pain in fibromyalgia in adults. Cochrane 
Database Syst Rev. 2016;9(9):CD011790. https://doi.
org/10.1002/14651858.CD011790.pub2
Dieleman JP, Kerklaan J, Huygen FJPM, Bouma PAD, 
Sturkenboom MCJM. Incidence rates and treatment of 
neuropathic pain conditions in the general population. 
Pain. 2008;137(3):681–688. https://doi.org/10.1016/j.
pain.2008.03.002 
Di Trapani G, Mei D, Marra C, Mazza S, Capuano A. Gabapentin 
in the prophylaxis of migraine: a double-blind randomized 
placebo-controlled study. Clin Ter. 2000;151(3):145–148
Domecq JP, Prutsky G, Leppin A et al. Clinical review: Drugs 
commonly associated with weight change: a systematic review 
and meta-analysis. J Clin Endocrinol Metab. 2015;100(2):363-
70. https://doi.org/10.1210/jc.2014-3421
electronic Medicines Compendium. Gabapentin 
600mg. 2017. https://www.medicines.org.uk/emc/
product/5002#UNDESIRABLE_EFFECTS (accessed 19 June 
2018)
electronic Medicines Compendium. Pregabalin 
300mg. 2018. https://www.medicines.org.uk/emc/
product/7444#UNDESIRABLE_EFFECTS (accessed 19 June 
2018)
Eroglu C, Allen NJ, Susman MW et al. Gabapentin receptor 
alpha2delta-1 is a neuronal thrombospondin receptor 
responsible for excitatory CNS synaptogenesis. Cell. 
2009;139(2):380-92. https://doi.org/10.1016/j.cell.2009.09.025
Finnerup NB, Attal N, Haroutounian S et al. Pharmacotherapy 
for neuropathic pain in adults: a systematic review and 
meta-analysis. Lancet Neurol. 2015;14(2):162-73. https://doi.
org/10.1016/S1474-4422(14)70251-0
Freynhagen R, Backonja M, Schug S et al. Pregabalin for the 
Treatment of Drug and Alcohol Withdrawal Symptoms: A 
Comprehensive Review. CNS Drugs. 2016;30(12):1191–1200. 
https://doi.org/10.1007/s40263-016-0390-z
Gee NS, Brown JP, Dissanayake VUK, Offord J, Thurlow R, 
Woodruff GN. The novel anticonvulsant drug, gabapentin 
(Neurontin), binds to the alpha2delta subunit of a calcium 
channel. J Biol Chem. 1996;271(10):5768–5776. https://doi.
org/10.1074/jbc.271.10.5768
Ghinea N, Lipworth W, Kerridge I. Evidence, regulation and 
‘rational’ prescribing: the case of gabapentin for neuropathic 
pain. J Eval Clin Pract. 2015;21(1):28-33. https://doi.
org/10.1111/jep.12223 
Guay DRP. Pregabalin in neuropathic pain: A more 
“pharmaceutically elegant” gabapentin? Am J Geriatr 
Pharmacother. 2005;3(4):274–287. https://doi.org/10.1016/j.
amjopharm.2005.12.008
Nurse Prescribing 2018 Vol 16 No 7 9
Pharmacology
©
 2018 M
A
 H
ealthcare Ltd
Guglielmo R, Martinotti G, Clerici M, Janiri L. Pregabalin for 
alcohol dependence: a critical review of the literature. Adv 
Ther. 2012;29(11):947–957. https://doi.org/10.1007/s12325-
012-0061-5
Häkkinen M, Vuori E, Kalso E, Gergov M, Ojanperä I. Profiles 
of pregabalin and gabapentin abuse by postmortem 
toxicology. Forensic Sci Int. 2014;241:1–6. doi:10.1016/j.
forsciint.2014.04.028
Hara K, Sata T. Inhibitory effect of gabapentin on N-methyl-
d-aspartate receptors expressed in Xenopus oocytes. Acta 
Anaesthesiol Scand. 2007;51(1):122–128. https://doi.
org/10.1111/j.1399-6576.2006.01183.x
Iacobucci G. UK government to reclassify pregabalin and 
gabapentin after rise in deaths. BMJ. 2017 Sep 25;358:j4441.
https://doi.org/10.1136/bmj.j4441
Linde M, Mulleners WM, Chronicle EP, McCrory DC. Gabapentin 
or pregabalin for the prophylaxis of episodic migraine in 
adults. Cochrane Database Syst Rev. 2013;(6):CD010609. 
doi:10.1002/14651858.CD010609
Lobo IA, Harris RA. GABAA receptors and alcohol. Pharmacol 
Biochem Behav. 2008;90(1):90–94. https://doi.org/10.1016/j.
pbb.2008.03.006
Lyndon A, Audrey S, Wells C et al. Risk to heroin users of 
polydrug use of pregabalin or gabapentin. Addiction. 
2017;112(9):1580-1589. https://doi.org/10.1111/add.13843
Iversen L. Re: Pregabalin and gabapentin advice. 2016. https://
www.gov.uk/government/uploads/system/uploads/attachment_
data/file/491854/ACMD_Advice_-_Pregabalin_and_
gabapentin.pdf. (accessed 7 June 2018)
Jallon P, Picard F. Bodyweight gain and anticonvulsants: a 
comparative review. Drug Saf. 2001;24(13):969-78
Johannessen Landmark C, Patsalos PN. Drug interactions 
involving the new second- and third-generation antiepileptic 
drugs. Expert Rev Neurother. 2010 Jan;10(1):119-40. https://
doi.org/10.1586/ern.09.136 
Johnson RW. Zoster-associated pain: what is known, who is at risk 
and how can it be managed? Herpes. 2007;14 Suppl 2:30-4
Jones D, Sorkin L. Systemic gabapentin and 3-isobutyl-
aminobutyric acid block secondary hyperalgesia. Brain Res. 
1998 Nov 9;810(1-2):93-9
Kim YS, Chu Y, Han L et al. Central terminal sensitization of 
TRPV1 by descending serotonergic facilitation modulates 
chronic pain. Neuron. 2014 Feb 19;81(4):873-887. https://doi.
org/10.1016/j.neuron.2013.12.011
Martinez V, Pichard X, Fletcher D. Perioperative pregabalin 
administration does not prevent chronic postoperative 
pain: systematic review with a meta-analysis of randomized 
trials. Pain. 2017;158(5):775-783.https://doi.org/10.1097/j.
pain.0000000000000838 
Martinotti G, Lupi M, Sarchione F et al. The potential of 
pregabalin in neurology, psychiatry and addiction: a qualitative 
overview. Curr Pharm Des. 2013;19(35):6367-74
Medicines and Healthcare Products Regulatory Agency. Off-label 
or unlicensed use of medicines: prescribers’ responsibilities. 
2009. https://www.gov.uk/drug-safety-update/off-label-or-
unlicensed-use-of-medicines-prescribers-responsibilities 
(accessed 19 June 2018)
Medicines and Healthcare Products Regulatory Agency. 
Gabapentin (Neurontin): risk of severe respiratory depression. 
2017. https://www.gov.uk/drug-safety-update/gabapentin-
neurontin-risk-of-severe-respiratory-depression (accessed 19 
June 2018)
Mersfelder TL, Nichols WH. Gabapentin: abuse, dependence and 
withdrawal. Ann Pharmacother. 2016;50(8):692. https://doi.
org/10.1177/1060028016655426
Millar J, Sadasivan S, Weatherup N, Lutton S. Lyrica nights–
recreational pregabalin abuse in an urban emergency 
department. Emerg Med J. 2013;30:874
Moore RA, Straube S, Wiffen PJ, Derry S, McQuay HJ. 
Pregabalin for acute and chronic pain in adults. Cochrane 
Database Syst Rev. 2009 Jul 8;(3):CD007076. https://doi.
org/10.1002/14651858.CD007076.pub2
Morrison EE, Sandilands EA, Webb DJ. Gabapentin and 
pregabalin: do the benefits outweigh the harms?J R Coll 
Physicians Edinb. 2017 Dec;47(4):310-313. https://doi.
org/10.4997/JRCPE.2017.402
Moulin D, Boulanger A, Clark AJ et al; Canadian Pain Society. 
Pharmacological management of chronic neuropathic pain: 
revised consensus statement from the Canadian Pain Society. 
Pain Res Manag. 2014 Nov-Dec;19(6):328-35 
Mulla SM, Wang L, Khokhar R et al. Management of central 
poststroke pain: systematic review of randomized controlled 
trials. Stroke. 2015;46(10):2853-60. https://doi.org/10.1161/
STROKEAHA.115.010259
Newman M. Bitter pills for drug companies. BMJ 2010; 341. 
https://doi.org/10.1136/bmj.c5095
PrescQipp. Neuropathic pain: Pregabalin and gabapentin 
prescribing. 2016. https://www.prescqipp.info/care-homes-
covert-admin/send/80-pregabalin-in-neuropathic-pain/2463-
bulletin-119-neuropathic-pain (accessed 11 June 2018)
National Institute for Health and Care Excellence. Clinical 
Knowledge Summaries. Neuropathic Pain-drug treatment. 
2015. https://cks.nice.org.uk/neuropathic-pain-drug-
treatment#!scenario (accessed 11 June 2018)
CPD reflective questions
■ What are the properties of gabapentin and pregabalin which 
make them useful for treating neuropathic pain?
■ What are the properties of gabapentin and pregabalin which 
make them attractive for misuse?
■ What areas of safety netting are going to be important to 
consider when prescribing these drugs?
■ Why has it become popular to prescribe outside of the 
licensed indications for use?
■ What will you consider discussing with patients before 
initiating these drugs?
■ Why is it important to avoid abrupt withdrawal?
Key Points
■ There is satisfactory evidence that gabapentin and 
pregabalin can be used as effective interventions for certain 
types of neuropathic pain, mainly painful diabetic neuropathy 
and post-herpetic neuralgia
■ Due consideration must be given to prescribing gabapentin 
or pregabalin for off-label uses
■ A detailed understanding of initiating, using, and stopping 
these drugs is required for safe practice
■ The propensity for misuse must form part of the prescribing 
decision-making process, as well as patient counselling
■ The UK status of pregabalin is likely to change to a controlled 
drug in the near future
Pharmacology
10 Nurse Prescribing 2018 Vol 16 No 7
©
 2
01
8 
M
A
 H
ea
lth
ca
re
 L
td
National Institute for Health and Care Excellence. Clinical 
Knowledge Summaries. Sciatica (lumbar radiculopathy). 2017a. 
https://cks.nice.org.uk/sciatica-lumbar-radiculopathy#!scenario 
(accessed 11 June 2018) 
National Institute for Health and Care Excellence. Clinical 
Knowledge Summaries. Post-herpetic neuralgia. 2017b. https://
cks.nice.org.uk/post-herpetic-neuralgia#!scenariorecommenda
tion (accessed 11 June 2018) 
National Institute for Health and Care Excellence. Clinical 
guideline CG173 Neuropathic Pain Pharmacological 
Management-Full Guideline. 2018a. http:// guidance.nice.org.
uk/CG173/Guidance/pdf/English (accessed 11 June 2018)
National Institute for Health and Care Excellence. Clinical 
Knowledge Summaries. Migraine. 2018b. https://cks.nice.org.
uk/migraine#!scenario (accessed 11 June 2018)
O’Connell NE, Wand BM, McAuley J, Marston L, Moseley 
G. Interventions for treating pain and disability in adults 
with complex regional pain syndrome- an overview of 
systematic reviews. Cochrane Database Syst Rev. 2013 Apr 
30;(4):CD009416. https://doi.org/10.1002/14651858.CD009416.
pub2
Office for National Statistics. Deaths related to drug poisoning  
in England and Wales: 2016 registrations. https://
www.ons.gov.uk/peoplepopulationandcommunity/
birthsdeathsandmarriages/deaths/bulletins/deathsrelatedtodru
gpoisoninginenglandandwales/2016registrations#people-aged-
40-to-49-years-have-the-highest-rate-of-drug-misuse-deaths 
(accessed 11 June 2018)
Oulis P, Konstantakopoulos G. Efficacy and safety of pregabalin 
in the treatment of alcohol and benzodiazepine dependence. 
Expert Opin Investig Drugs. 2012 Jul;21(7):1019-29. https://
doi.org/10.1517/13543784.2012.685651
Parsons G. Guide to the management of gabapentinoid misuse. 
Prescriber. 2018; 29:25-30 
Patsalos PN. Drug interactions with the newer antiepileptic  
drugs (AEDs)–part 1: pharmacokinetic and pharmacodynamic 
interactions between AEDs. Clin Pharmacokinet.  
2013 Nov;52(11):927-66. https://doi.org/10.1007/s40262-013-
0087-0
Public Health England. Advice for prescribers on the risk of the 
misuse of pregabalin and gabapentin. https://assets.publishing.
service.gov.uk/government/uploads/system/uploads/
attachment_data/file/385791/PHE-NHS_England_pregabalin_
and_gabapentin_advice_Dec_2014.pdf (accessed 11 June 2018)
Rajan RS, de Gray L, George E. Painful diabetic neuropathy. 
Continuing Education in Anaesthesia Critical Care and Pain. 
2014; 14(5):230–235
Reccoppa L, Malcolm R, Ware M. Gabapentin abuse in inmates 
with prior history of cocaine dependence. Am J Addict. 2004 
May-;13(3):321-3. https://doi.org/10.1080/10550490490460300
Rockett M. (2014) Diagnosis, mechanisms and treatment 
of complex regional pain syndrome. Curr Opin 
Anaesthesiol. 2014;27(5):494-500. https://doi.org/10.1097/
ACO.0000000000000114
Schifano F, D’Offizi S, Piccione M et al. Is there a recreational 
misuse potential for pregabalin? Analysis of anecdotal online 
reports in comparison with related gabapentin and clonazepam 
data. Psychother Psychosom. 2011;80(2):118-22. https://doi.
org/10.1159/000321079 
Smith BH, Higgins C, Baldacchino A, Kidd B, Bannister 
J. Substance misuse of gabapentin. Br J Gen Pract. 
2012;62(601):406-7. https://doi.org/10.3399/bjgp12X653516 
Smith RV, Havens JR, Walsh SL. Gabapentin misuse, abuse and 
diversion: a systematic review. Addiction. 2016;111(7):1160-74. 
https://doi.org/10.1111/add.13324 
Smith RV, Lofwall MR, Havens JR. Abuse and diversion  
of gabapentin among nonmedical prescription opioid users  
in Appalachian Kentucky. Am J Psychiatry. 2015;172(5): 
487-8. https://doi.org/10.1176/appi.ajp.2014.14101272 
Spence D. Bad medicine: gabapentin and pregabalin. BMJ. 
2013;347:f6747. https://doi.org/10.1136/bmj.f6747
Spira PJ, Beran RG; Australian Gabapentin Chronic Daily 
Headache Group. Gabapentin in the prophylaxis of chronic 
daily headache: a randomized, placebo-controlled study. 
Neurology. 2003;61(12):1753-9
Stahl SM. Anticonvulsants as anxiolytics, part 2: pregabalin and 
gabapentin as alpha(2)delta ligands at voltage-gated calcium 
channels.J Clin Psychiatry. 2004;65(4):460-1
Steinman MA, Bero LA, Chren MM, Landefeld CS. Narrative 
review: the promotion of gabapentin: an analysis of internal 
industry documents. Ann Intern Med. 2006;145(4):284-93
Straube S, Derry S, Moore RA, Wiffen PJ, McQuay HJ. Single 
dose oral gabapentin for established acute postoperative pain 
in adults. Cochrane Database Syst Rev. 2010;(5):CD008183. 
https://doi.org/ 10.1002/14651858.CD008183.pub2 
Tanabe M, Takasu K, Kasuya N, Shimizu S, Honda M, Ono H. 
Role of descending noradrenergic system and spinal alpha2‐
adrenergic receptors in the effects of gabapentin on thermal 
and mechanical nociception after partial nerve injury in the 
mouse. Br J Pharmacol. 2005;144(5):703-14
Taylor CP. Mechanisms of action of gabapentin. Rev Neurol 
(Paris). 1997;153 Suppl 1:S39-45
Taylor CP, Gee NS, Su TZ et al. A summary of mechanistic 
hypotheses of gabapentin pharmacology. Epilepsy Res. 
1998;29(3):233-49.
Tiippana EM, Hamunen K, Kontinen VK, Kalso E. Do surgical 
patients benefit from perioperative gabapentin/pregabalin? 
A systematic review of efficacy and safety. Anesth Analg. 
2007;104(6):1545-56
Treiman DM. GABAergic mechanisms in epilepsy. Epilepsia. 
2001;42(Suppl 3):8-12
UK Medicines Information. How do you switch between 
pregabalin and gabapentin for neuropathic pain, and vice 
versa? https://www.evidence.nhs. uk/h?q=%22How+do+you+s
witch+between+pregabalin+and+gabapentin+for+neuropathic
+pain% 2C+and+vice+versa%22. (accessed 11 June 2018)
Watson JC, Sandroni P. Central neuropathic pain syndromes. 
Mayo Clin Proc. 2016;91(3):372-85.  https://doi.org/10.1016/j.
mayocp.2016.01.017
Wiffen PJ, Derry S, Bell RF, Rice ASC, Tölle T, Phillips T, 
Moore R.Gabapentin for chronic neuropathic pain in adults. 
Cochrane Database Syst Rev. 2017;6:CD007938. https://doi.
org/10.1002/14651858.CD007938.pub4
Wilens T, Zulauf C, Ryland D, Carrellas N, Catalina-Wellington 
I.  Prescription medication misuse among opioid dependent 
patients seeking inpatient detoxification. Am J Addict. 
2015;24(2):173-7. https://doi.org/10.1111/ajad.12159 
Wilkinson P, Whiteman R. Pain management programmes, BJA 
Education. 2017;17(1):10–15. https://doi.org/10.1093/bjaed/
mkw027
Woolf CJ. Central sensitization: implications for the diagnosis and 
treatment of pain. Pain. 2011;152(3 Suppl):S2-15. https://doi.
org/ 10.1016/j.pain.2010.09.030 
Yang RH, Wang WT, Chen JY, Xie RG, Hu SJ. Gabapentin 
selectively reduces persistent sodium current in injured type‐A 
dorsal root ganglion neurons. Pain. 2009;143(1-2):48-55.  
https://doi.org/10.1016/j.pain.2009.01.020
Huang Y, Thathiah A. Regulation of neuronal communication by 
G protein-coupled receptors. FEBS Lett. 2015;589(14):1607-19. 
https://doi.org/ 10.1016/j.febslet.2015.05.007
